IMS Solutions, a University of Birmingham and Imperial College London spin-out, has raised £1.1 million to commercialize mass spectrometry-based steroid biomarker tests for adrenal cancer and PMOS, with clinical validation underway.
Waters has introduced the Xevo TQ Absolute XR IVD Mass Spectrometer, featuring up to five times greater sensitivity for clinical applications at the 2026 ADLM Annual Meeting.
Finding themselves in a vicious tug-of-war, clinical labs are struggling to keep pace with emerging designer drugs.
The collaboration will use multi-omic platforms and AI-driven analytics to identify disease patterns and improve patient stratification within the PRECISE-SG100K study.
The approval expands the company's automated mass spectrometry menu to 39 tests.
The automated, PCR-free DNA library prep solution is designed for whole genome sequencing, targeting mid-throughput clinical and translational labs.